Prime Medicine (PRME) CEO Reine received 1,300,000 Stock Option (right to buy)
Insider transactions reported
Allan Reine (Chief Executive Officer at Prime Medicine Inc., PRME) reported that they received 1,300,000 Stock Option (right to buy) on Feb 26, 2026.
- Reporting person
- Reine Allan
- Role
- Chief Executive Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Grant or award (A) | Stock Option (right to buy)On 1,300,000 Common Stock1 | +1,300,000 | - | - | 1,300,000 direct |
Holdings before and after
- Stock Option (right to buy): 0 to 1,300,000 direct
Footnotes from the filing
- 1. 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 26, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Reine report in this PRME Form 4?
Allan Reine (Chief Executive Officer at Prime Medicine Inc., PRME) reported that they received 1,300,000 Stock Option (right to buy) on Feb 26, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for PRME
Across the 8 sessions after earlier PRME headlines, the stock closed higher 5 times and lower 3 times, with a median move of 9.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PRME | SPY |
|---|---|---|---|
| Feb 25, 2026 | Prime Medicine to Participate in Upcoming Investor Conferences | +7.8% | +0.8% |
| Jan 7, 2026 | Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference | +9.2% | -0.3% |
| Dec 8, 2025 | Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease | +12.6% | -0.3% |
| Nov 25, 2025 | Prime Medicine to Present at 8th Annual Evercore Healthcare Conference | -1.8% | +0.9% |
| Nov 11, 2025 | Prime Medicine to Present at Jefferies Global Healthcare Conference | +11.2% | +0.2% |
| Nov 7, 2025 | CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updatesand 1 other headline that session | -8.9% | +0.1% |
Earlier insider filings at PRME
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2022
Follow PRME and get a push notification the moment its next story breaks.